ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1198

Intra-Articular Hyaluronic Acid Delay to Total Knee Arthroplasty By Number of Injection Courses Received: Analysis of an Administrative Database

Andrew Concoff1, Faizan Niazi2, Peter Shaw2 and Jeffrey Rosen3, 1Rheumatology, St. Jude Medical Center, Fullerton, CA, 2Ferring Pharmaceuticals Inc., Parsippany, NJ, 3Department of Orthopaedics & Rehabilitation, New York Presbyterian Queens; Department of Clinical Orthopaedic Surgery, Weill Medical College of Cornell University, New York, NY, New York, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: hyaluronate and osteoarthritis, Knee

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Total knee arthroplasty (TKA) is the standard surgical treatment for patients with osteoarthritis (OA) that no longer experience symptom relief from conservative or pharmacologic treatments. Intra-articular hyaluronic acid (IA-HA) is a common treatment option for mild to moderate knee OA that provides relief for patients who do not respond to conservative treatment and are not ready for TKA. The primary objective of this study is to determine if there is a correlation between receiving IA-HA injections and a delay to TKA in patients with knee OA compared to patients not receiving IA-HA, and if more courses of IA-HA injections relates to a longer delay to TKA.

Methods: This was a retrospective analysis of the Blue Cross/ Blue Shield (BCBS) claims database from October 1st, 2010 through September 30th, 2015. The primary outcome was time to TKA, which was defined as the time from treatment to the time TKA. Kaplan-Meier survival analysis was conducted to determine the TKA-free survival of patients who received IA-HA injections stratified by the number of injection courses received versus those who did not receive any IA-HA injections. A Cox proportional hazards regression analysis was also conducted to compare hazards ratios between the non IA-HA treated group and the IA-HA injection subgroups.

Results: A total of 744,734 patients were included in the analysis. Of these, 181,631 received at least one IA-HA injection, while 563,103 did not receive an IA-HA injection. A delay to TKA compared to the non IA-HA treated group was generally observed within the first year after IA-HA treatment for patients treated with 1 injection course, while patients treated with multiple courses demonstrated an incremental increase in delay to TKA with more injections (Figure 1). The model demonstrated a gradual decrease in hazard ratio (HR) with each subsequent course of IA-HA injection in comparison to the no IA-HA injection group, suggesting that the risk of TKA is reduced with subsequent IA-HA courses. The hazard ratio for a single course of injections was 0.85 (95% CI 0.84 – 0.86). The HR for TKA was smallest in the 5 or more injection courses group (HR 0.27, 95% CI 0.25 to 0.28).

Conclusion: These results demonstrate that within a large cohort of knee OA patients, individuals who received multiple courses of HA injections had a progressively greater delay to TKA compared to patients who did not receive HA treatment. The results demonstrated that with a greater number of injection courses received over time, there may be a relationship to a longer delay in TKA. Based on these results, multiple, repeat courses of IA-HA injection may be beneficial in substantially delaying TKA in knee OA patients.

Figure 1: Survival Analysis


Disclosure: A. Concoff, Ferring Pharmaceuticals Inc, 5; F. Niazi, Ferring Pharmaceuticals Inc., 3; P. Shaw, Ferring Pharmaceuticals Inc., 3; J. Rosen, Ferring Pharmaceuticals Inc., 5,Flexion, 5,Novartis Pharmaceutical Corporation, 5,OrthoGenrx, 5.

To cite this abstract in AMA style:

Concoff A, Niazi F, Shaw P, Rosen J. Intra-Articular Hyaluronic Acid Delay to Total Knee Arthroplasty By Number of Injection Courses Received: Analysis of an Administrative Database [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/intra-articular-hyaluronic-acid-delay-to-total-knee-arthroplasty-by-number-of-injection-courses-received-analysis-of-an-administrative-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intra-articular-hyaluronic-acid-delay-to-total-knee-arthroplasty-by-number-of-injection-courses-received-analysis-of-an-administrative-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology